Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Cell Biol Int ; 33(1): 19-30, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18996492

RESUMEN

Previous studies in our lab have identified pre-B-cell colony enhancing factor (PBEF) as a novel biomarker in acute lung injury. This study continues to elucidate the underlying molecular mechanism of PBEF in the pathogenesis of acute lung injury in pulmonary cell culture models. Our results revealed that IL-1beta induced PBEF expression in pulmonary vascular endothelial cells at the transcriptional level and a -1535 T-variant in the human PBEF gene promoter significantly attenuated its binding to an IL-1beta-induced unknown transcription factor. This may underlie the reduced expression of PBEF and thus the lower susceptibility to acute lung injury in -1535T carriers. Furthermore, overexpression of PBEF significantly augmented IL-8 secretion and mRNA expression by more than 6-fold and 2-fold in A549 cells and HPAEC, respectively. It also significantly augmented IL-1beta-mediated cell permeability by 44% in A549 cells and 65% in endothelial cells. The knockdown of PBEF expression significantly inhibited IL-1beta-stimulated IL-8 secretion and mRNA level by 60% and 70%, respectively, and the knockdown of PBEF expression also significantly attenuated IL-1beta-induced cell permeability by 29% in epithelial cells and 24% in endothelial cells. PBEF expression also affected the expression of two other inflammatory cytokines (IL-16 and CCR3 genes). These results suggest that PBEF is critically involved in pulmonary vascular and epithelial inflammation and permeability, which are hallmark features in the pathogenesis of acute lung injury. This study lends further support to our finding that PBEF is a potential new target in acute lung injury.


Asunto(s)
Citocinas/genética , Nicotinamida Fosforribosiltransferasa/genética , Neumonía/etiología , Lesión Pulmonar Aguda/diagnóstico , Lesión Pulmonar Aguda/etiología , Sustitución de Aminoácidos , Secuencia de Bases , Línea Celular Tumoral , Proliferación Celular , Citocinas/metabolismo , Cartilla de ADN , Relación Dosis-Respuesta a Droga , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Expresión Génica , Técnicas de Silenciamiento del Gen , Humanos , Interleucina-16/genética , Interleucina-1beta/metabolismo , Interleucina-8/genética , Interleucina-8/metabolismo , Nicotinamida Fosforribosiltransferasa/metabolismo , Permeabilidad , Polimorfismo de Nucleótido Simple , ARN Mensajero/metabolismo , ARN Interferente Pequeño , Receptores CCR3/genética , Factores de Tiempo
2.
Bioorg Med Chem ; 16(2): 995-1005, 2008 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-17950607

RESUMEN

Series of cationic lipids 1a-p, with variable length of hydrocarbon chains, alternative quaternary ammonium heads, carbamate linkages between hydrocarbon chains and quaternary ammonium heads, as well as different anion combined with them, were synthesized for liposome-mediated gene delivery. Two plasmid DNAs, pGL3-control and pGFP-N2, were transferred by cationic liposomes formed from the above cationic lipids into five mammalian cell lines, and the transfection efficiency of some of the cationic liposomes was superior or parallel to that of two commercial transfection agents, Lipofectamine2000 and Sofast.


Asunto(s)
Carbamatos/síntesis química , Portadores de Fármacos , Terapia Genética , Lípidos/síntesis química , Liposomas/química , Transfección/métodos , Carbamatos/química , Técnicas de Transferencia de Gen , Lípidos/química , Compuestos de Amonio Cuaternario/química
3.
Int J Biochem Cell Biol ; 37(6): 1219-31, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15778086

RESUMEN

Human ribonuclease inhibitor (RI) is a cytoplasmic acidic protein. The experiment demonstrated that it might effectively inhibit tumor-induced angiogenesis and inhibit tumor growth. Ribonuclease inhibitor is constructed almost entirely of leucine-rich repeats, which might be involved in unknown biological effects besides inhibiting RNase A and angiogenin activities. The exact molecular mechanism of antitumor on ribonuclease inhibitor remains unclear so far. In order to further understand the function of ribonuclease inhibitor and investigate the relationship with tumor growth, our study established a transfection of human ribonuclease inhibitor cDNA into the murine B16 cells by the retroviral packaging cell line PA317. The cell line transfected with a stably high expression of ribonuclease inhibitor was identified. We found that the transfected ribonuclease inhibitor could obviously inhibit cell proliferation, regulate cell cycle and induce cell apoptosis in vitro. Mice that were injected with the B16 cells transfected RI cDNA showed a significant inhibition of the tumor growth with lighter tumor weight, lower density of microvessels, longer latent periods, and survival time than those in the other two control groups. In conclusion, the results reveal the novel mechanism that antitumor effect of ribonuclease inhibitor is also associated with inducing apoptosis, regulating cell cycle and inhibiting proliferation besides antiangiogenesis. These results suggest that ribonuclease inhibitor might be a candidate of tumor suppressor gene in some tissues. RI could become a target gene for gene therapy. Our study may be of biological and clinical importance.


Asunto(s)
Melanoma Experimental/patología , Hormonas Placentarias/genética , Hormonas Placentarias/farmacología , Inhibidores de la Angiogénesis/farmacología , Animales , Apoptosis/efectos de los fármacos , Caspasa 3 , Caspasas/biosíntesis , Humanos , Melanoma Experimental/tratamiento farmacológico , Ratones , Ratones Endogámicos C57BL , Hormonas Placentarias/uso terapéutico , Transfección
4.
Cancer Gene Ther ; 12(3): 268-75, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15592448

RESUMEN

Human ribonuclease inhibitor (hRI) is an acid protein with a molecular weight of 50 kDa. It can inhibit the activity of pancreatic RNase (RNase A). Angiogenin (Ang) is a member of the ribonuclease super family. It has 35% identity with RNase A and contains ribonucleolytic activity. The substrate specificity of angiogenin seems, however, to be more restricted than that of the pancreatic RNase. Since Ang is an important angiogenic factor and RI is a highly efficient inhibitor of Ang, it can be hypothesized that RI may be a latent antiangiogenic drug. This study focuses on the feasibility of transfecting the ri gene into mice hematopoietic cells and inducing the expression of the ri gene to block the angiogenesis of solid tumors. First, the cDNA gene of the ri from human placenta was cloned and inserted in a retroviral vector, pLNCX. The combined vector pLNCX-ri was transfected into retroviral packaging cells, PA317, and a clone producing a high titer of virus was obtained. Next, isolated hematopoietic cells from mice bone marrow were infected with viruses carrying the pLNCX-ri. The infected cells were then injected into lethally irradiated mice. The expression and the contribution of RI were assayed in vivo. After administration of hematopoietic cells carrying the ri gene, mice were implanted with B16 melanomas for 21 days. The results showed that tumors of control groups became large and well vascularized. In contrast, tumors from mice groups treated with hematopoietic cells carrying the ri gene were small and possessed a relatively low density of blood vessels. The inhibited growth rate of the tumors was 47%. This study demonstrated the potential utility of gene therapy for systemic delivery of a novel antiangiogenic agent--hRI.


Asunto(s)
Inhibidores de la Angiogénesis/genética , Regulación de la Expresión Génica , Terapia Genética/métodos , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/metabolismo , Melanoma/terapia , Hormonas Placentarias/genética , Inhibidores de la Angiogénesis/metabolismo , Animales , Western Blotting , Clonación Molecular , Cartilla de ADN , ADN Complementario/genética , Técnica del Anticuerpo Fluorescente , Técnicas de Transferencia de Gen , Vectores Genéticos/genética , Humanos , Masculino , Melanoma/genética , Ratones , Ratones Endogámicos C57BL , Hormonas Placentarias/metabolismo , Retroviridae , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Ribonucleasa Pancreática/antagonistas & inhibidores , Transgenes/genética , Trasplante Heterólogo
5.
Yi Chuan ; 27(2): 249-54, 2005 Mar.
Artículo en Zh | MEDLINE | ID: mdl-15843355

RESUMEN

Human placental ribonuclease inhibitor is an acidic protein of Mr approximately 50 kDa with unusually high contents of leucine and cysteine. It is a cytosolic protein that protects cells from the adventitious invasion of pancreatic-type ribonuclease. HRI has 32 cysteine residues, and the oxidative formation of disulfide bonds from those cysteine residues is a rapid cooperative process that inactivates HRI. The most proximal cysteine residues in native HRI are two pairs that are adjacent in sequence. In the present paper, two molecules of alanine to substitute for cys328/cys329 were performed by site-directed mutagenesis. The site-mutated RI cDNA was constructed into plasmid pPIC9K, and then transformed Pichia pastoris GS115 by electroporation. After colony screening , the bacterium was cultured and the product was purified with affinity chromatography. The affinity of the recombinant human RI with double site mutation was examined for RNase A and its anti-oxidative effect. The results indicated that there was no much change in the affinity for RNase A detected when compared with the wild type of RI. But the capacity of anti-oxidative effect was increased by 7-9 times. The enhance in anti-oxidative effect might be the reason for preventing the formation of disulfide bond between cys328 and cys329 and the three dimensional structure of RI was thereby maintained.


Asunto(s)
Mutagénesis Sitio-Dirigida/métodos , Pichia/genética , Hormonas Placentarias/genética , Alanina/genética , Sustitución de Aminoácidos , Antioxidantes/metabolismo , Antioxidantes/farmacología , Western Blotting , Catálisis/efectos de los fármacos , Cisteína/genética , Electroporación , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/farmacología , Expresión Génica , Humanos , Peróxido de Hidrógeno/farmacología , Mutación , Pichia/metabolismo , Hormonas Placentarias/metabolismo , Hormonas Placentarias/farmacología , Plásmidos , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/farmacología , Ribonucleasa Pancreática/antagonistas & inhibidores , Ribonucleasa Pancreática/metabolismo , Transformación Genética
6.
Zhonghua Zhong Liu Za Zhi ; 26(12): 722-5, 2004 Dec.
Artículo en Zh | MEDLINE | ID: mdl-15733388

RESUMEN

OBJECTIVE: To investigate the effect of ginsenoside-Rg3 on lung metastasis of ribonuclease inhibitor (RI) gene-transfected mouse B16 melanoma. METHODS: C57BL/6 mice were iv injected with parental or RI-transfected B16 melanoma cells. Lung metastasis was assessed by the number of surface tumor nodules. Mice were divided into 6 groups. Group I, II and III of mice were given parental, mock-transfected and RI-transfected B16 melanoma cells, respectively while in group IV, V and VI, Rg3 (1.5 mg/kg, iv q.o.d. x 10) was given to mice bearing parental, mock-transfected and RI-transfected B16 melanoma, respectively. Micovessel density (MVD) of the lung metastatic tumor was assessed by immunohistochemical staining of factor VIII-R expression. RESULTS: The number of tumor nodules was significantly decreased in mice injected with RI-transfected B16 melanoma (Gp III, compared to Gp I and II). Rg3 treatment per se could also decrease the number of lung tumor nodules but to a lesser extent (Gp IV and V compared to Gp III). However, Rg3 synergized with RI transfection resulting in most significant inhibition of lung metastasis (Gp VI). Mice in Gp I and II died within 26 days of the experiment, whereas all the mice in Gp VI were alive during the observation period of one and one half month. MVD was significantly decreased in the lung tumor nodules in mice injected with RI-transfected B16 melanoma. It was further decreased when additional Rg3 was given (Gp VI). CONCLUSION: Transfection of ribonuclease inhibitor gene significantly reduces the metastatic potential of B16 melanoma. Ginsenoside-Rg3 has a synergistic effect.


Asunto(s)
Ginsenósidos/farmacología , Neoplasias Pulmonares/secundario , Melanoma Experimental/patología , Hormonas Placentarias/genética , Transfección , Animales , Antineoplásicos Fitogénicos/farmacología , Línea Celular Tumoral , Ginsenósidos/aislamiento & purificación , Neoplasias Pulmonares/patología , Masculino , Melanoma Experimental/genética , Ratones , Ratones Endogámicos C57BL , Trasplante de Neoplasias , Panax/química
8.
Ai Zheng ; 28(3): 236-43, 2009 Mar.
Artículo en Zh | MEDLINE | ID: mdl-19619436

RESUMEN

BACKGROUND AND OBJECTIVE: Human ribonuclease inhibitor (hRI) extracted and purified from human placenta has been shown to remarkably inhibit some solid tumors in mice. This study was to construct V-pLNCX-s-hri, a secretory expression vector, and explore its inhibition effects on the growth of mouse B16 melanoma cells. METHODS: The hRI gene sequence conjugated with the synthesized signal peptide of mouse IgG was cloned into the retroviral vector V-pLNCX to construct V-pLNCX-s-hri. The PA317 cells were used for viral package and NIH3T3 cells were employed to determine the viral titer. The expression of hRI gene was detected by RT-PCR and Western blot. The content of RI was determined by enzyme-linked immunoabsorption assay (ELISA). The model of B16 melanoma-carrying mouse was established and received different treatments. The tumor weight and microvessle density (MVD) were assessed. Normal saline (NS), V-pLNCX, and V-pLNCX-hri were used as controls. RESULTS: The infection efficiency of V-pLNCX-s-hri on cultured B16 cells reached 38.5%. mRNA and protein levels of hRI were detected in B16 cells infected by V-pLNCX-s-hri. The hRI content in the supernatant of infected B16 cells reached 0.228 microg/mL. The hRI content in the peripheral blood of experimental mice was significantly higher in the V-pLNCX-s-hri group (0.249 microg/mL) than in the NS group (0.035 microg/mL), V-pLNCX group (0.028 microg/mL) and V-pLNCX-hri group (0.169 microg/mL) (P<0.01). The tumor weight and MVD were significantly lower in the V-pLNCX-s-hri group compared with those in the NS, V-pLNCX and V-pLNCX-hri groups (P>0.01). CONCLUSIONS: V-pLNCX-s-hri can effectively infect B16 cells and induce high expression of hRI. V-pLNCX-s-hri is superior to V-pLNCX-hri in inhibiting the growth of B16 cells.


Asunto(s)
Proliferación Celular , Melanoma Experimental/patología , Neovascularización Patológica/prevención & control , Hormonas Placentarias/biosíntesis , Ribonucleasas/antagonistas & inhibidores , Animales , Femenino , Regulación Neoplásica de la Expresión Génica , Vectores Genéticos , Inmunoglobulina G/genética , Masculino , Melanoma Experimental/metabolismo , Ratones , Ratones Endogámicos C57BL , Microvasos/patología , Células 3T3 NIH , Hormonas Placentarias/genética , ARN Mensajero/metabolismo , Distribución Aleatoria , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/genética , Retroviridae/genética , Transfección
9.
Chem Biol Drug Des ; 71(4): 336-44, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18312294

RESUMEN

Transfection activities of two series of synthetic glycerol backbone-based cationic lipids were studied as gene delivery carriers. The variable length of hydrocarbon chains, diverse quaternary ammonium heads, different linkage, as well as alternative anion combined with them allowed to find how these factors affect cationic lipids on their gene delivery performance. The structure-function relationship of the synthetic glycerol backbone-based cationic lipids was discussed, and the transfection efficiency of some of the cationic liposomes was superior or parallel to that of two commercial transfection agents.


Asunto(s)
Técnicas de Transferencia de Gen , Glicerol/química , Liposomas/metabolismo , Animales , Carbamatos/química , Cationes/química , Línea Celular , Supervivencia Celular , ADN/metabolismo , Éteres/química , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Liposomas/química , Relación Estructura-Actividad , Transfección/métodos
10.
J Pharmacol Exp Ther ; 316(3): 1025-30, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16299188

RESUMEN

The pleiotropic effects of estrogen are mediated via stimulation of two estrogen receptor (ER) subtypes, ERalpha and ERbeta. Although a number of studies have identified expression of one or both subtypes in estrogen target tissues, fewer studies have correlated ER expression with a functional role of these proteins in regulating cellular excitability. In the present study, we have combined cellular fluorescence, immunocytochemistry, and molecular expression techniques with single-channel patch-clamp studies to determine which ER mediates estrogen-stimulated potassium channel activity in human coronary artery smooth muscle cells (HCASMC). We had demonstrated previously that estrogen stimulates activity of the large-conductance, calcium- and voltage-activated potassium (BK(Ca)) channel in HCASMC via a nongenomic mechanism. We now demonstrate expression of both ERalpha and ERbeta subtypes in HCASMC. Functionally, however, expression of ERalpha antisense plasmid abolished the acute effect of estrogen on these channels, whereas estrogen retained its ability to stimulate BK(Ca) channels in cells transfected with only green fluorescence protein. In contrast, overexpression of ERalpha enhanced the stimulatory action of estrogen in HCASMC. Transfection with ERalpha antisense/sense plasmid did not alter ERbeta expression. These findings indicate that the ERalpha isoform mediates estrogen-induced stimulation of BK(Ca) channels in HCASMC and thereby provide evidence for a receptor-dependent signaling mechanism that can mediate estrogen-induced inhibition of cellular excitability.


Asunto(s)
Vasos Coronarios/metabolismo , Receptor alfa de Estrógeno/fisiología , Músculo Liso Vascular/metabolismo , Miocitos del Músculo Liso/metabolismo , Canales de Potasio Calcio-Activados/fisiología , Western Blotting , Células Cultivadas , Estradiol/análogos & derivados , Estradiol/farmacología , Receptor alfa de Estrógeno/análisis , Receptor alfa de Estrógeno/genética , Receptor beta de Estrógeno/análisis , Fulvestrant , Humanos , Músculo Liso Vascular/citología , Óxido Nítrico/biosíntesis , ARN Mensajero/análisis , Transfección
11.
Sheng Wu Gong Cheng Xue Bao ; 21(1): 36-41, 2005 Jan.
Artículo en Zh | MEDLINE | ID: mdl-15859326

RESUMEN

In order to explore the transfection and expression of hRI gene on human umbilical blood stem cells, and observe it's effect on the tumor growth. After enriching human umbilical cord blood CD34+ cells with a high-gradient magnetic cell sorting system (MACS), transfected them with supernatant of retrovirus containing human Ribonuclease inhibitor (hRI) cDNA. Hematopoietic progenitor clonogenic assay and PCR were used to evaluate transfection efficiency, and Western-blot and immune fluorescence were used to evaluate the expression quantity of hRI gene after transfection. Observe the effect of RI on the growth of melonoma in B16C57BL mice. The results showed that human umbilical blood CD34+ cells were highly purified by MACS, which made the purity of human umbilical blood CD34+ cells average 96.15%. hRI can be transfected on umbilical blood CD34+ cells, and the transfection efficiency was 35%. The positive expression of hRI gene on transfected CD34+ cells is identified by Western-blot and immune fluorescence assay. Mice injected with transfected CD34+ cells show a significant restraint of the tumor growth, a lower efficiency of tumor formation, a lower weight of the tumor and a longer incubation period of tumor formation with respect to the control groups. The results demonstrated the capacity of RI to inhibited the tumor growth by blocking the vasculature in tumor.


Asunto(s)
Terapia Genética , Células Madre Hematopoyéticas/metabolismo , Melanoma/terapia , Proteínas del Tejido Nervioso/genética , Transfección , Animales , Antígenos CD34/metabolismo , Proliferación Celular/efectos de los fármacos , Sangre Fetal/citología , Humanos , Melanoma/patología , Ratones , Ratones Endogámicos C57BL , Proteínas del Tejido Nervioso/biosíntesis , Células Tumorales Cultivadas
12.
Ai Zheng ; 23(3): 269-72, 2004 Mar.
Artículo en Zh | MEDLINE | ID: mdl-15025955

RESUMEN

BACKGROUND & OBJECTIVE: Ribonuclease inhibitor (RI), which is rich in human placenta, is a multi-functional acidic glycoprotein. Our previous studies showed that the growth of some solid tumors (S180 sarcoma, Ca761 breast cancer, and H22 hepatoma) could be significantly inhibited by RI extracted and purified from human placenta. This study was designed to observe the change of RI gene expression in human breast cancer tissue. METHODS: The expression level of RI mRNA was determined by reverse transcription-polymerase chain reaction (RT-PCR) and capillary electrophoresis (CE). The RI content was determined by Western blot analysis. RESULTS: The electrophoretic stripes of the RT-PCR products of the breast cancer tissues were narrower and the plaques of Western blot of the breast cancer tissues were smaller compared with the control breast tissues. The peak altitude and width of capillary electrophoretic absorptive curve of the RT-PCR product of the breast cancer tissue were clearly smaller than that of the control breast tissue. The capillary electrophoresis integral values of the absorptive peak areas of RT-PCR product of the breast cancer tissue and the control breast tissue were (3.320+/-0.365)x10(6) and (4.385+/-0.880)x10(6), respectively. The comparison between two groups reveals a remarkably difference (P< 0.01). CONCLUSION: The gene expression of RI is clearly down-regulated in human breast cancer tissue that the RI mRNA level is remarkably lower and RI content also reduces significantly in human breast cancer tissue.


Asunto(s)
Neoplasias de la Mama/genética , Inhibidores Enzimáticos/metabolismo , Regulación Neoplásica de la Expresión Génica , Hormonas Placentarias/genética , Western Blotting , Femenino , Humanos , ARN Mensajero/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
13.
Ai Zheng ; 23(11): 1249-56, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15522168

RESUMEN

BACKGROUND & OBJECTIVE: Human ribonuclease inhibitor (RI) could effectively block angiogenin-induced angiogenesis, and inhibit growth of transplant solid tumors in animals. However, its exact molecular mechanism of antitumor has not been totally ascertained. Many tumor suppressor genes occur loss of expression by aberrant methylation in promoter region. Demethylation, treated with methylation inhibitor 5-aza-2'-deoxycytidine (5-Aza-CdR),can restore the gene expression. To further explore functions of RI, and investigate relationship between RI and tumorigenesis, the study was designed to explore effects of 5-Aza-CdR on expression of RI in cancer cell lines. METHODS: Human breast cancer cell line MCF-7, human gastric cancer cell line BGC-823, human prostate cancer cell line DU-145, and human colon cancer cell line HT-29 were treated with 5-Aza-CdR. Expression of RI was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR), Western blot, immunofluorescence, and immunocytochemistry. RESULTS: Expression of RI significantly elevated by 5-Aza-CdR at both mRNA and protein level in MCF-7, BGC-823, and DU-145 cells (P< 0.01). Compared with control cells, mRNA levels of RI in MCF-7, BGC-823, and DU-145 cells treated with 5-Aza-CdR were increased by percentages of 37.2%, 46.0%, and 32.4%, respectively; protein levels of RI were increased by percentages of 26.4%, 20.9%, and 24.4%, respectively; but no obvious change observed in HT-29 cells. CONCLUSION: RI gene may be involved in tumorigenesis of gastric, prostate, and breast cancer.


Asunto(s)
Azacitidina/análogos & derivados , Neoplasias de la Mama/metabolismo , Proteínas del Tejido Nervioso/biosíntesis , Neoplasias de la Próstata/metabolismo , Neoplasias Gástricas/metabolismo , Azacitidina/farmacología , Neoplasias de la Mama/patología , Línea Celular Tumoral , Neoplasias del Colon/metabolismo , Neoplasias del Colon/patología , Metilación de ADN , Metilasas de Modificación del ADN/antagonistas & inhibidores , Decitabina , Regulación hacia Abajo , Femenino , Humanos , Masculino , Proteínas del Tejido Nervioso/genética , Neoplasias de la Próstata/patología , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Neoplasias Gástricas/patología
14.
Mol Reprod Dev ; 61(1): 126-34, 2002 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11774384

RESUMEN

A 1933 bp cDNA fragment, coding a truncated testis-specific novel nucleoporin, was isolated from a human testis lambdaZAPII cDNA library, designated as BS-63 and assigned GenBank accession number: U64675. By applying the methods of rapid amplification of cDNA ends (5' RACE) and PCR, a full-length BS-63 cDNA composed of 5475 bp was obtained. BS-63 cDNA contained an open reading frame consisting of 1765 codons and XFXFG or GLFG repetitive sequence motifs. These repetitive motifs are structural characteristic of nucleoporins. BS-63 cDNA has high homology with Nup358/Ran BP2. A 1599 bp fragment, corresponding to the C-terminus of BS-63 cDNA, was prepared and expressed in E. coli BL21(DE3). The recombinant product was purified by affinity chromatography and SDS-PAGE and polyclonal antibodies raised. In rat testis section, the BS-63 protein was localized at the sites of nuclear pores in spermatids by immuno-gold transmission electron microscopy and on the nuclear membrane of Triton X-treated sperm by colloidal silver immuno-gold scanning electron microscopy. The recombinant BS-63 protein can be phosphorylated in vitro with PKC and p34(cdc2). A yeast two-hybrid system was used to screen a mouse testis cDNA library to identify proteins capable of interacting with BS-63. Using the 1.6 kb cDNA fragment as bait, the following interacting proteins were identified: Ran, transportin (karyopherin beta2), two proteins related to the nucleocytoplasmic transporter and aF10 protein. The latter protein is a putative transcriptor containing a cysteine-rich N-terminus, a LAP/PHD finger, a leucine zipper domain and a glutamine-rich C-terminus. Also it is highly expressed in murine testis and is located in the cell nucleus and cytoplasm. The interaction of BS-63 with aF10 (696-1001aa) was validated by surface plasmon resonance and by affinity precipitation combined with Western blot. aF10 (696-1001aa) interacted in vitro with BS-63 extracted from rat testis germ cells. It is hypothesized that BS-63 is a testis-specific nucleoporin and possibly acts as a docking site and a cotransporter of Ran and transportin. The complex performs the task of a carrier system in transporting aF10 into the nucleus of germ cells during spermiogenesis.


Asunto(s)
Glicoproteínas/genética , Glicoproteínas/metabolismo , Testículo/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Clonación Molecular , ADN Complementario/genética , Glicoproteínas/química , Glicoproteínas/aislamiento & purificación , Humanos , Carioferinas/química , Masculino , Ratones , Microscopía Electrónica de Rastreo , Datos de Secuencia Molecular , Membrana Nuclear/química , Membrana Nuclear/metabolismo , Poro Nuclear/química , Poro Nuclear/metabolismo , Proteínas de Complejo Poro Nuclear , Proteínas Nucleares , Especificidad de Órganos , Fosforilación , Unión Proteica , Proteína Quinasa C/metabolismo , Transporte de Proteínas , Homología de Secuencia de Ácido Nucleico , Espermatozoides/citología , Espermatozoides/metabolismo , Espermatozoides/ultraestructura , Testículo/citología , Factores de Transcripción/metabolismo , Técnicas del Sistema de Dos Híbridos , Proteína de Unión al GTP ran/química
15.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 20(5): 572-4, 2004 Sep.
Artículo en Zh | MEDLINE | ID: mdl-15367350

RESUMEN

AIM: To prepare and purify the antibody against ribonuclease inhibitor(RI). METHODS: RI was extracted from human placenta and purified by affinity chromatography. Rabbits anti-RI antibody was obtained after immunization and then purified through rProtein A Sepharose Fast Flow chromatography column. The characters of the antibody was identified by SDS-PAGE, ELISA and Western blot. RESULTS: An anti-RI antibody was obtained and purified. SDS-PAGE analysis showed that the purified anti-RI antibody has high purity. The results of Western blot and ELISA indicated that anti-RI antibody had high specificity and good stability. CONCLUSION: The anti-RI antibody with high titer, high specificity and good stability has been acquired, which lays the foundation for further research on RI.


Asunto(s)
Anticuerpos/aislamiento & purificación , Especificidad de Anticuerpos , Sueros Inmunes/aislamiento & purificación , Placenta/química , Hormonas Placentarias/inmunología , Animales , Femenino , Humanos , Inmunización , Masculino , Hormonas Placentarias/aislamiento & purificación , Embarazo , Conejos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA